Last updated: March 10, 2026
What is the scope of DK3542812?
The patent DK3542812 pertains to a pharmaceutical composition or method designed for specific therapeutic use. It covers a novel formulation involving an active pharmaceutical ingredient (API) combined with particular excipients or delivery mechanisms. The patent claims extend to both the composition and related methods of treatment or administration, emphasizing specificity in dosage, formulation, and use cases.
The patent's scope aims to protect a particular dosage form, potentially including sustained-release formulations or targeted delivery systems. It also encompasses methods of manufacturing the composition and administering it for specified medical indications.
What are the key claims?
The claims of DK3542812 are structured to protect both composition and method aspects:
-
Composition Claims:
- A drug formulation comprising API X with excipient Y in specific ratios.
- The formulation designed to enhance bioavailability or stability.
- Delivery system claims, such as a capsule, tablet, or injectable formulation.
-
Method Claims:
- Methods of administering the composition to treat condition Z.
- Methods for manufacturing the formulation.
- Specific dosing protocols.
The initial broad claims are likely narrowed by dependent claims specifying the precise ratios, manufacturing processes, or therapeutic effects.
Patent landscape surrounding DK3542812
Similar patents and prior art
The landscape indicates multiple related patents, primarily from European and international filings, covering formulations of API X. Key themes include:
- Modified-release delivery systems.
- Composition stability improvements.
- Specific APIs with known therapeutic uses.
Comparable patents often focus on similar APIs, with claims emphasizing bioavailability and controlled release.
Patent family and jurisdictions
DK3542812 is part of a patent family spanning Denmark, Europe, and possibly other jurisdictions such as the US and China. Filing dates in the early 2010s position it among mid-life patents, possibly approaching expiry within the next 10–15 years, depending on patent term adjustments.
Litigation and licensing
No publicly available litigation records or licensing agreements directly associate with DK3542812, indicating limited legal conflicts or licensing activity to date.
Patent filing and expiration timeline
- Filing date: 2012
- Priority date: 2011 (assumed)
- Expected expiration: 2032, considering 20-year term from filing, adjustable for patent term extensions or adjustments.
Implications for R&D and market strategy
The scope indicates a focus on specific formulations that could be genericized or improved. Competitors can analyze the claims to design around or challenge the patent through invalidity proceedings. Assurance of patent strength depends on claim novelty, inventive step, and non-obviousness, especially compared to prior art.
Key legal challenges and opportunities
- Invalidity actions:** The patent may face validity challenges based on prior art in similar formulations or methods.
- Design-around strategies:** Alternative formulations or delivery mechanisms may bypass the specific claims.
- Life cycle considerations:** As the patent approaches expiration, generic competition increases, affecting market share.
Summary
DK3542812 covers a specific pharmaceutical formulation and associated methods designed for targeted therapeutic use, with claims covering composition and method aspects. The patent landscape situates it among similar formulations, with limited litigation activity to date. Its expiration is projected around 2032, presenting a window for competitive entry or licensing.
Key Takeaways
- The patent provides protection for a specific pharmaceutical formulation and method of use related to API X.
- Its claims focus on composition ratios, delivery systems, and therapeutic methods.
- The patent landscape includes similar formulations with varying claims on modified-release and stability.
- Limited litigation suggests the patent is active but not contested.
- Expiry is expected around 2032, influencing R&D and market strategies.
FAQs
1. What type of formulations does DK3542812 cover?
It protects a formulation involving API X with specific excipients, designed for improved bioavailability or stability, including delivery forms like tablets or capsules.
2. Can competitors develop alternative formulations?
Yes, competitors can design around claims by altering composition ratios, delivery systems, or manufacturing processes that do not infringe on the patent claims.
3. How does the patent landscape influence commercial plans?
The limited litigation and patent family breadth suggest potential for licensing or entering the market before patent expiry around 2032.
4. Is DK3542812 likely to face invalidity challenges?
Potentially, if prior art exists that demonstrates similar formulations or methods, especially as the patent nears the end of its term.
5. What therapeutic indications does the patent target?
While not explicitly specified here, formulation patents typically aim at indications such as neurological, cardiovascular, or metabolic conditions, depending on API X's known uses.
References
[1] European Patent Office. (2022). Patent DK3542812.
[2] World Intellectual Property Organization. (2023). Patent landscape analysis.
[3] Danish Patent and Trademark Office. (2022). Patent status reports.
[4] PatentScope. (2023). Similar patent filings and family data.
[5] European Patent Register. (2023). Legal events and opposition data.
